Compare Bristol-Myers Squibb Co (BMY) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Invesco Preferred ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.41 (market cap $129.94B), while Invesco Preferred ETF trades at $10.64. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while Invesco Preferred ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals.
| BMY | PGX | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | — |
52-Week High | $65.89 | $11.87 |
52-Week Low | $42.60 | $10.65 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
